Why the study?
Does pretreatment ambulatory blood pressure better predict long-term mortality than office blood pressure in treated elderly hypertensives?
Does pretreatment ambulatory blood pressure better predict long-term mortality than office blood pressure in treated elderly hypertensives?
Pretreatment night-time ambulatory blood pressure is a superior predictor of long-term mortality compared to office blood pressure in treated elderly hypertensive patients.
Answers are grounded in this paper and cite their sources.
Nighttime ABP best predicts mortality in treated elderly hypertensives; extends Syst-Eur but leaves open whether it should guide therapy.
BACKGROUND: Numerous studies have shown a stronger relationship between ambulatory blood pressure (ABP), particularly night ABP, and cardiovascular events/mortality than for office blood pressure (OBP). A previous clinical trial (Syst-Eur) showed that pretreatment ABP was only a better predictor of outcome than OBP in placebo-treated participants. The current study in treated elderly hypertensives from the Second Australian National Blood Pressure study (ANBP2) examined whether pretreatment ABP was a better predictor of mortality than OBP over long-term (∼11 years) follow-up. PARTICIPANTS AND METHODS: ANBP2 was a comparative outcome trial in 6083 off-treatment or previously untreated elderly hypertensives. In the ABP substudy, at study entry, participants had ABP and nurse-performed OBP measurements. Cox proportional hazards analysis assessed the relationships between both OBP and ABP at study entry and 11-year all-cause and cardiovascular mortality, with results pooled from both active treatment phases. RESULTS: In 702 participants, over a median of 10.8 years, including 6.7 years after the trial, 167 died (82 cardiovascular). Pretreatment 'night' systolic ABP and pulse pressure were the best predictors of '11-year' cardiovascular mortality (hazard ratios: 1.26; 95% confidence intervals: 1.10-1.45, P=0.001 and 1.18; 1.06-1.31, P=0.003, respectively) and all-cause mortality (hazard ratios: 1.15; 95% confidence intervals:1.05-1.28, P=0.005 and 1.09; 1.10-1.31, P=0.03, respectively). OBP was not a significant predictor of mortality. CONCLUSION: In actively treated elderly hypertensives participating in ANBP2, all-cause or cardiovascular deaths were significantly related to pretreatment ABP, particularly to night-time systolic ABP and pulse pressure, but not to OBP.
No takes yet. Share an insight, caveat, or question.
Wing et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: